Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Edward C. Mun is active.

Publication


Featured researches published by Edward C. Mun.


Proceedings of the National Academy of Sciences of the United States of America | 2003

Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1

Mary-Elizabeth Patti; Atul J. Butte; Sarah Crunkhorn; Kenneth Cusi; Rachele Berria; Sangeeta R. Kashyap; Yoshinori Miyazaki; Isaac S. Kohane; Maura Costello; Robert Saccone; Edwin J. Landaker; Allison B. Goldfine; Edward C. Mun; Ralph A. DeFronzo; Jean Finlayson; C. Ronald Kahn; Lawrence J. Mandarino

Type 2 diabetes mellitus (DM) is characterized by insulin resistance and pancreatic β cell dysfunction. In high-risk subjects, the earliest detectable abnormality is insulin resistance in skeletal muscle. Impaired insulin-mediated signaling, gene expression, glycogen synthesis, and accumulation of intramyocellular triglycerides have all been linked with insulin resistance, but no specific defect responsible for insulin resistance and DM has been identified in humans. To identify genes potentially important in the pathogenesis of DM, we analyzed gene expression in skeletal muscle from healthy metabolically characterized nondiabetic (family history negative and positive for DM) and diabetic Mexican–American subjects. We demonstrate that insulin resistance and DM associate with reduced expression of multiple nuclear respiratory factor-1 (NRF-1)-dependent genes encoding key enzymes in oxidative metabolism and mitochondrial function. Although NRF-1 expression is decreased only in diabetic subjects, expression of both PPARγ coactivator 1-α and-β (PGC1-α/PPARGC1 and PGC1-β/PERC), coactivators of NRF-1 and PPARγ-dependent transcription, is decreased in both diabetic subjects and family history-positive nondiabetic subjects. Decreased PGC1 expression may be responsible for decreased expression of NRF-dependent genes, leading to the metabolic disturbances characteristic of insulin resistance and DM.


Obesity | 2009

Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism

Mary-Elizabeth Patti; Sander M. Houten; Antonio C. Bianco; Raquel Bernier; P. Reed Larsen; Jens J. Holst; Michael K. Badman; Eleftheria Maratos-Flier; Edward C. Mun; Jussi Pihlajamäki; Johan Auwerx; Allison B. Goldfine

The multifactorial mechanisms promoting weight loss and improved metabolism following Roux‐en‐Y gastric bypass (GB) surgery remain incompletely understood. Recent rodent studies suggest that bile acids can mediate energy homeostasis by activating the G‐protein coupled receptor TGR5 and the type 2 thyroid hormone deiodinase. Altered gastrointestinal anatomy following GB could affect enterohepatic recirculation of bile acids. We assessed whether circulating bile acid concentrations differ in patients who previously underwent GB, which might then contribute to improved metabolic homeostasis. We performed cross‐sectional analysis of fasting serum bile acid composition and both fasting and post‐meal metabolic variables, in three subject groups: (i) post‐GB surgery (n = 9), (ii) without GB matched to preoperative BMI of the index cohort (n = 5), and (iii) without GB matched to current BMI of the index cohort (n = 10). Total serum bile acid concentrations were higher in GB (8.90 ± 4.84 µmol/l) than in both overweight (3.59 ± 1.95, P = 0.005, Ov) and severely obese (3.86 ± 1.51, P = 0.045, MOb). Bile acid subfractions taurochenodeoxycholic, taurodeoxycholic, glycocholic, glycochenodeoxycholic, and glycodeoxycholic acids were all significantly higher in GB compared to Ov (P < 0.05). Total bile acids were inversely correlated with 2‐h post‐meal glucose (r = −0.59, P < 0.003) and fasting triglycerides (r = −0.40, P = 0.05), and positively correlated with adiponectin (r = −0.48, P < 0.02) and peak glucagon‐like peptide‐1 (GLP‐1) (r = 0.58, P < 0.003). Total bile acids strongly correlated inversely with thyrotropic hormone (TSH) (r = −0.57, P = 0.004). Together, our data suggest that altered bile acid levels and composition may contribute to improved glucose and lipid metabolism in patients who have had GB.


Diabetologia | 2005

Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia.

Mary-Elizabeth Patti; Graham T. McMahon; Edward C. Mun; Asaf Bitton; Jens J. Holst; Jeffrey D. Goldsmith; Douglas W. Hanto; Mark P. Callery; Ronald A. Arky; Vania Nose; Susan Bonner-Weir; Allison B. Goldfine

Aims/hypothesisPostprandial hypoglycaemia following gastric bypass for obesity is considered a late manifestation of the dumping syndrome and can usually be managed with dietary modification. We investigated three patients with severe postprandial hypoglycaemia and hyperinsulinaemia unresponsive to diet, octreotide and diazoxide with the aim of elucidating the pathological mechanisms involved.MethodsGlucose, insulin, and C-peptide were measured in the fasting and postprandial state, and insulin secretion was assessed following selective intra-arterial calcium injection. Pancreas histopathology was assessed in all three patients.ResultsAll three patients had evidence of severe postprandial hyperinsulinaemia and hypoglycaemia. In one patient, reversal of gastric bypass was ineffective in reversing hypoglycaemia. All three patients ultimately required partial pancreatectomy for control of neuroglycopenia; pancreas pathology of all patients revealed diffuse islet hyperplasia and expansion of beta cell mass.Conclusions/interpretationThese findings suggest that gastric bypass-induced weight loss may unmask an underlying beta cell defect or contribute to pathological islet hyperplasia, perhaps via glucagon-like peptide 1-mediated pathways.


Obesity | 2006

Peptide YY levels are elevated after gastric bypass surgery

Jean L. Chan; Edward C. Mun; Violeta Stoyneva; Christos S. Mantzoros; Allison B. Goldfine

Objective: Mechanisms that promote effective and sustained weight loss in persons who have undergone Roux‐en‐Y gastric bypass surgery are incompletely understood but may be mediated, in part, by changes in appetite. Peptide YY (PYY) is a gut‐derived hormone with anorectic properties. We sought to determine whether gastric bypass surgery alters PYY levels or response to glucose.


The Journal of Clinical Endocrinology and Metabolism | 2009

Thyroid hormone-related regulation of gene expression in human fatty liver

Jussi Pihlajamäki; Tanner Boes; Eun-Young Kim; Farrell Dearie; Brian W. Kim; Joshua Schroeder; Edward C. Mun; Imad Nasser; Peter J. Park; Antonio C. Bianco; Allison B. Goldfine; Mary-Elizabeth Patti

CONTEXT Fatty liver is an important complication of obesity; however, regulatory mechanisms mediating altered gene expression patterns have not been identified. OBJECTIVE The aim of the study was to identify novel transcriptional changes in human liver that could contribute to hepatic lipid accumulation and associated insulin resistance, type 2 diabetes, and nonalcoholic steatohepatitis. DESIGN We evaluated gene expression in surgical liver biopsies from 13 obese (nine with type 2 diabetes) and five control subjects using Affymetrix U133A microarrays. PCR validation was performed in liver biopsies using an additional 16 subjects. We also tested thyroid hormone responses in mice fed chow or high-fat diet. SETTING Recruitment was performed in an academic medical center. PARTICIPANTS Individuals undergoing elective surgery for obesity or gallstones participated in the study. RESULTS The top-ranking gene set, down-regulated in obese subjects, was comprised of genes previously demonstrated to be positively regulated by T(3) in human skeletal muscle (n = 399; P < 0.001; false discovery rate = 0.07). This gene set included genes related to RNA metabolism (SNRPE, HNRPH3, TIA1, and SFRS2), protein catabolism (PSMA1, PSMD12, USP9X, IBE2B, USP16, and PCMT1), and energy metabolism (ATP5C1, COX7C, UQCRB). We verified thyroid hormone regulation of these genes in the liver after injection of C57BL/6J mice with T(3) (100 microg/100 g body weight); furthermore, T(3)-induced increases in expression of these genes were abolished by high-fat diet. In agreement, expression of these genes inversely correlated with liver fat content in humans. CONCLUSIONS These data suggest that impaired thyroid hormone action may contribute to altered patterns of gene expression in fatty liver.


Journal of Clinical Investigation | 2011

Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance

Wanzhu Jin; Allison B. Goldfine; Tanner Boes; Robert R. Henry; Theodore P. Ciaraldi; Eun-Young Kim; Merve Emecan; Connor Fitzpatrick; Anish Sen; Ankit Shah; Edward C. Mun; Martha Vokes; Joshua Schroeder; Elizabeth Tatro; Jose Jimenez-Chillaron; Mary-Elizabeth Patti

Insulin resistance in skeletal muscle is a key phenotype associated with type 2 diabetes (T2D) for which the molecular mediators remain unclear. We therefore conducted an expression analysis of human muscle biopsies from patients with T2D; normoglycemic but insulin-resistant subjects with a parental family history (FH(+)) of T2D; and family history-negative control individuals (FH(–)). Actin cytoskeleton genes regulated by serum response factor (SRF) and its coactivator megakaryoblastic leukemia 1 (MKL1) had increased expression in T2D and FH(+) groups. Furthermore, striated muscle activator of Rho signaling (STARS), an activator of SRF, was upregulated in T2D and FH(+) and was inversely correlated with insulin sensitivity. Skeletal muscle from insulin-resistant mice recapitulated this gene expression pattern and showed reduced G-actin and increased nuclear localization of MKL1, each of which regulates SRF activity. Overexpression of MKL1 or reduction in G-actin decreased insulin-stimulated Akt phosphorylation, whereas reduction of STARS expression increased insulin signaling and glucose uptake. Pharmacological SRF inhibition by CCG-1423 reduced nuclear MKL1 and improved glucose uptake and tolerance in insulin-resistant mice in vivo. Thus, SRF pathway alterations are linked to insulin resistance, may contribute to T2D pathogenesis, and could represent therapeutic targets.


Gastroenterology | 1998

Levamisole inhibits intestinal Cl- secretion via basolateral K+ channel blockade.

Edward C. Mun; Julio M. Mayol; Martin Riegler; Timothy C. O'Brien; Omid C. Farokhzad; Jaekyung C. Song; Charalabos Pothoulakis; Bruce J. Hrnjez; Jeffrey B. Matthews

BACKGROUND & AIMS Phenylimidazothiazoles have recently been shown to activate wild-type and mutant cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channels in transfected cells and were proposed as therapy for cystic fibrosis. The aim of this study was to investigate the effects of phenylimidazothiazoles on regulated transepithelial Cl- transport in intact epithelia. METHODS T84 intestinal epithelial cells grown on permeable supports and stripped human colonic mucosal sheets were studied by conventional current-voltage clamping. Selective permeabilization of apical or basolateral membranes with the monovalent ionophore nystatin was used to isolate basolateral K+ and apical Cl- channel activity, respectively. 86Rb+ uptake was assessed for Na/K/2Cl cotransporter and Na+,K(+)-adenosine triphosphatase activity. RESULTS In T84 monolayers and human colon, levamisole and its brominated derivative bromotetramisole failed to activate transepithelial secretion. In fact, these compounds dose-dependently inhibited secretory responses to the cyclic adenosine monophosphate agonist forskolin and the Ca2+ agonist carbachol. In permeabilized T84 monolayers, phenylimidazothiazoles weakly activated apical Cl- currents (consistent with their reported action on CFTR) and did not affect bumetanide-sensitive or bumetanide-insensitive 86+Rb+ uptake. Instead, they profoundly inhibited the basolateral Ba(2+)-sensitive and Ba(2+)-insensitive K+ currents. CONCLUSIONS Phenylimidazothiazoles block K+ channels required for Cl(-)-secretory responses elicited by diverse pathways in model epithelia and native colon, an effect that outweighs their ability to activate apical Cl- channels.


Current Opinion in Endocrinology & Diabetes | 2006

Hyperinsulinemic hypoglycemia following gastric bypass surgery for obesity

Allison B. Goldfine; Edward C. Mun; Mary-Elizabeth Patti

Purpose of reviewTo examine the recently recognized association between bariatric surgery-induced weight loss and postprandial hyperinsulinemic hypoglycemia. Recent findingsPostprandial hypoglycemia following gastric bypass for obesity is generally considered a late manifestation of the dumping syndrome and can usually be managed with dietary modification. A rare syndrome characterized by more severe postprandial hypoglycemia and hyperinsulinemia, accompanied by diffuse pancreatic islet hyperplasia and expansion of beta-cell mass, however, has recently been identified. In our experience, the therapeutic approach to these patients is guided by the severity and frequency of hypoglycemia, and includes nutritional modification to reduce postprandial glycemic excursion and stepped medical management, including acarbose, octreotide and diazoxide. Other therapeutic agents previously used to inhibit insulin secretion or action, including calcium channel blockade, β-blockers and anticholinergics, have been minimally effective. For life-threatening hypoglycemia refractory to medical management, partial pancreatectomy may be necessary, but hypoglycemia has recurred in some patients. These findings suggest that gastric bypass-induced weight loss may unmask an underlying beta-cell defect or contribute to pathologic islet hyperplasia. SummarySevere postprandial hyperinsulinemic hypoglycemia may be regarded as a rare, late complication of bariatric surgery. Management of these patients may require nutritional, pharmacological and, on occasion, surgical intervention. The pathophysiology remains incompletely understood.


Journal of Cellular Physiology | 1999

Protein kinase C activation downregulates the expression and function of the basolateral Na+/K+/2Cl− cotransporter

Omid C. Farokhzad; G.D. Vivek Sagar; Edward C. Mun; Jason K. Sicklick; Margaret M. Lotz; Jeremy A. Smith; Jaekyung C. Song; Timothy C. O'Brien; C. Pal Sharma; T. Bernard Kinane; Richard A. Hodin; Jeffrey B. Matthews

The basolateral Na+/K+/2Cl− cotransporter (NKCC1) has been shown to be an independent regulatory site for electrogenic Cl− secretion. The proinflammatory phorbol ester, phorbol 12‐myristate 13‐acetate (PMA), which activates protein kinase C (PKC), inhibits basal and cyclic adenosine monophosphate (cAMP)‐stimulated NKCC1 activity in T84 intestinal epithelial cells and decreases the steady state levels of NKCC1 mRNA in a time‐ and dose‐dependent manner. The levels of NKCC1 protein also fall in accordance with the NKCC1 mRNA transcript and these levels are unaffected by 4α‐phorbol, which does not activate PKC. Inhibition of maximal (cAMP‐stimulated) NKCC1 functional activity by PMA was first detected by 1 h, whereas decreases in the steady state levels of NKCC1 mRNA were not detectable until 4 h. NKCC1 mRNA expression recovers toward control levels with extended treatment of cells with PMA suggesting that the PMA effects on NKCC1 expression are mediated through activation of PKC. Although NKCC1 mRNA and protein levels return to control values after extended PMA exposure, NKCC1 functional activity does not recover. Immunofluorescence imaging suggest that the absence of functional recovery is due to failure of newly synthesized NKKC1 protein to reach the cell surface. We conclude that NKCC1 has the capacity to be regulated at the level of de novo expression by PKC, although decreased NKCC1 expression alone cannot account for either early or late loss of NKCC1 function. J. Cell. Physiol. 181:489–498, 1999.


Surgery | 1996

Adenosine scavenging: a novel mechanism of chloride secretory control in intestinal epithelial cells.

Kevin J. Tally; Bruce J. Hrnjez; Jeremy A. Smith; Edward C. Mun; Jeffrey B. Matthews

BACKGROUND Adenosine released by cells during ischemia typically serves as a feedback inhibitor of further organ work. However, in ischemic intestine, adenosine appears to act via stimulatory A2b receptors to increase work in the form of chloride ion (Cl-) secretion. This unusual response may contribute to luminal fluid sequestration in intestinal ischemia. In nonischemic cells feed-forward activation of Cl- secretion does not occur despite the fact that adenosine may be continuously generated during normal cell metabolism. Thus we postulated that intestinal epithelia normally control the disposition of adenosine to prevent inappropriate activation of secretion. METHODS Model T84 intestinal epithelia were studied by means of electrophysiologic and isotopic techniques. RESULTS Dipyridamole and nitrobenzylthioinosine (inhibitors of nucleoside transport) and iodotubercidin (an inhibitor of adenosine kinase) caused adenosine to accumulate extracellularly and induced a Cl- secretory response that was prevented by adenosine receptor blockade. Uptake of exogenous adenosine was restricted to the basolateral compartment and was blocked by nucleoside transport inhibitors. CONCLUSIONS Adenosine released from nonischemic intestinal epithelial cells is scavenged by a basolaterally restricted adenosine transporter. This system maintains extracellular adenosine levels below the prosecretory threshold and thus limits adenosine-elicited activation of Cl- secretion (and hence diarrhea) under normal conditions).

Collaboration


Dive into the Edward C. Mun's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jaekyung C. Song

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Benjamin E. Schneider

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Celina M. Hanson

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Timothy C. O'Brien

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge